IBDEI0T9 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14434,1,5,0)
 ;;=5^Rheumatic Disease Tricuspid Valve
 ;;^UTILITY(U,$J,358.3,14434,2)
 ;;=^35528
 ;;^UTILITY(U,$J,358.3,14435,0)
 ;;=414.3^^89^892^17
 ;;^UTILITY(U,$J,358.3,14435,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14435,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,14435,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,14435,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,14436,0)
 ;;=414.4^^89^892^16
 ;;^UTILITY(U,$J,358.3,14436,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14436,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,14436,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,14436,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,14437,0)
 ;;=425.11^^89^892^60
 ;;^UTILITY(U,$J,358.3,14437,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14437,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,14437,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,14437,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,14438,0)
 ;;=425.18^^89^892^59
 ;;^UTILITY(U,$J,358.3,14438,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14438,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,14438,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,14438,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,14439,0)
 ;;=V12.55^^89^892^54
 ;;^UTILITY(U,$J,358.3,14439,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14439,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,14439,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,14439,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,14440,0)
 ;;=454.9^^89^892^84
 ;;^UTILITY(U,$J,358.3,14440,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14440,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,14440,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,14440,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,14441,0)
 ;;=271.3^^89^893^11
 ;;^UTILITY(U,$J,358.3,14441,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14441,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,14441,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,14441,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,14442,0)
 ;;=611.1^^89^893^16
 ;;^UTILITY(U,$J,358.3,14442,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14442,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,14442,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,14442,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,14443,0)
 ;;=704.1^^89^893^17
 ;;^UTILITY(U,$J,358.3,14443,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14443,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,14443,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,14443,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,14444,0)
 ;;=251.2^^89^893^30
 ;;^UTILITY(U,$J,358.3,14444,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14444,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,14444,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,14444,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,14445,0)
 ;;=253.2^^89^893^34
 ;;^UTILITY(U,$J,358.3,14445,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14445,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,14445,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,14445,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,14446,0)
 ;;=733.00^^89^893^43
 ;;^UTILITY(U,$J,358.3,14446,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14446,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,14446,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,14446,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,14447,0)
 ;;=278.00^^89^893^40
 ;;^UTILITY(U,$J,358.3,14447,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14447,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,14447,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,14447,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,14448,0)
 ;;=278.01^^89^893^39
 ;;^UTILITY(U,$J,358.3,14448,1,0)
 ;;=^358.31IA^5^2
